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Abstract. Fibrinogen has emerged as a promising therapeutic target against Alzheimer’s disease because of its dual role in
altered vascular function and amyloid- aggregation. Here we provide evidence regarding cognitive improvement and reduction
of brain parenchyma amyloid- deposition in APP/PS1 mice after treatment for one month with the fibrinogen-blocking peptide
Fib377−395. No alteration in glial response or other neuroinflammatory markers was observed in the cortex of treated animals.
Considering these results and the fact that Fib377−395 does not affect coagulation function, this peptide could be considered as
a promising and safe candidate for chronic treatment of Alzheimer’s disease.
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INTRODUCTION
Previous findings have demonstrated that the clot-
ting protein fibrinogen may play a relevant role in
Alzheimer’s disease (AD) by linking altered vascular
function and amyloid- (A) aggregation [1]. AD and
related animal models exhibit altered blood-brain bar-
rier permeability, decreased blood-flow, and increased
susceptibility to ischemia, thus supporting the vascular
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pathology as a relevant factor in AD [2]. Fibrino-
gen is not normally found in brain but blood-brain
barrier dysfunction caused by A vascular accumu-
lation, inflammatory processes, and ischemic episodes
likely facilitates fibrinogen extravasation in the brain
parenchyma. Extravascular fibrinogen potentiates, in
turn, blood-brain barrier permeability by decreasing
the levels of endothelial tight junction proteins. More
importantly, extravascular fibrinogen can interact
and co-deposit with A, enhancing A fibrilliza-
tion and fibrinogen oligomerization in cerebral vessel
walls and brain parenchyma leading to blood ves-
sel occlusion, hypoperfusion, synaptic dysfunction,
and neuronal degeneration [3–5]. Moreover, fibrinogen
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released in the brain parenchyma promotes neuroin-
flammatory responses [6], which have deleterious
effects when sustained chronically [7].
In light of these observations, blocking the activ-
ity of fibrinogen has emerged as a putative therapeutic
action to reduce vascular and A pathologies in AD.
In this line, genetic depletion of fibrinogen decreases
cerebral amyloid angiopathy and reduces cognitive
impairment in a transgenic model of AD [4]. Similarly,
the use of anticoagulant agents that remove fibrino-
gen from circulation is also beneficial in AD models,
in terms of reduced neurovascular damage and neu-
roinflammation [4, 6]. However, their practical use
in AD is limited because of the side effects related
to coagulation deficiency derived from their chronic
administration, particularly in the elderly [8].
The aim of the present study was to test the ther-
apeutic properties of the fibrinogen-derived 377−395
peptide (Fib377−395) in an animal model of AD. This
peptide is known to inhibit the interaction between
fibrinogen and the microglia integrin receptor Mac-
1 (CD11b/M2), resulting in an anti-inflammatory
effect in at least two animal models of degenerative
diseases, multiple sclerosis [9] and Duchenne muscu-
lar dystrophy [10, 11], without impairing fibrinogen’s
coagulation function. We have chosen the APP/PS1
mouse as a disease model because it replicates rele-
vant features of AD including cognitive impairment,
A deposition, and neuroinflammation [12, 13].
MATERIALS AND METHODS
Animals
Experiments were carried out on male APP/PS1
mice and wild-type (WT) littermates aged 6 months
(early symptomatic phase) at the onset of the study.
The generation of mice expressing the human mutated
forms APPswe and PS1dE9 (APP/PS1) has already
been described [12]. Animals were maintained under
standard housing conditions in a 12-h dark-light cycle
with free access to food and water. Mice were randomly
assigned to treatment groups (WT Vehicle: n = 7;
WT Fib377−395: n = 8; APP/PS1 Vehicle: n = 6;
APP/PS1 Fib377−395: n = 7) and the experiments
were conducted under blind experimental conditions.
All animal procedures were carried out following
the guidelines of the European Communities Coun-
cil Directive 2010/63/EU and with the approval of
the local ethical committees of the University of
Barcelona.
Pharmacological treatment
Fibrinogen 377−395 peptide (Y S M K E T T M K
I I P F N R L S I G; Azco Pharmchem, San Jose, CA,
US) at a concentration of 3 mg/mL or the correspond-
ing vehicle (0.9% NaCl) was administered intranasally
(5 L) to mice every other day for 4 weeks, as previ-
ously described [9].
Behavioral evaluation of memory performance
and sample collection
After a wash-out period (3 days), the memory perfor-
mance of the animals was evaluated in the two-object
recognition test, by using a V-maze as previously
described [13]. On day 1, mice were habituated for
9 min allowing them to freely explore the apparatus.
On the second day, mice were placed for 9 min in the
maze where two identical objects were situated at the
end of the arms, and the time that each mouse spent
exploring each object was recorded. Then, 24 h after
the training session, animals were placed again in the
V-maze where one of the two familiar objects was
replaced by a novel object. The time that the animals
spent exploring the two objects was recorded and an
object recognition index was calculated as the differ-
ence between the time spent exploring the novel and the
familiar object, divided by the total time spent explor-
ing the two objects. Animals with memory impairment
revealed a lower object recognition index. At the end
of the behavioral testing, the animals were killed and
their brains rapidly removed from the skull and pro-
cessed for study. One hemisphere was dissected on ice,
immediately frozen, and stored at −80◦C until used
for the gene expression study. The other hemisphere
was fixed in 4% paraformaldehyde and processed for
immunohistochemistry.
Aβ and fibrinogen immunohistochemistry
Fixed tissue samples were embedded in paraffin,
and coronal sections, 4 m thick, were cut with a
microtome. De-waxed sections were incubated with
98% formic acid (3 min, only for A immunostain-
ing) and then treated with citrate buffer (20 min) to
enhance antigenicity. Then endogenous peroxidases
were blocked by incubation in 10% methanol-1%
H2O2 solution (15 min). Sections were blocked with
3% normal horse serum solution and then incubated
at 4◦C overnight with the primary antibody against
total A (clone 6F/3D, mouse, 1:50, Dako, Glostrup,
Denmark) or fibrinogen (rabbit, 1:100, Abcam, UK).
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Sections were subsequently rinsed and incubated with
biotinylated secondary antibody (Dako), followed by
EnVision+ system peroxidase (Dako), and finally with
chromogendiaminobenzidineandH2O2.Sectionswere
lightly counterstained with hematoxylin. After stain-
ing, the sections were dehydrated and cover-slipped
for observation under a Nikon Eclipse E800 micro-
scope (Nikon Imaging Inc., Tokyo, Japan; Objective:
10×). The cortical total A burden was calculated as
the percentage of the area of amyloid deposition in
plaques with respect to the total area in 9 representa-
tive pictures taken of the cerebral cortex of each animal,
corresponding to the main regions where A deposition
is observed in APP/PS1 mice. A quantification was
calculatedusing theAdobe® Photoshop® CS4software
(Adobe Systems Inc., San Jose, CA, USA), as previ-
ously described [13]. The vascular A and fibrinogen
deposition was also quantified as the percentage of ves-
sels presenting A- or fibrinogen-specific staining in
a given brain section. Vessels were identified by their
morphology based on hematoxylin staining.
Aβ soluble quantification: Enzyme-linked
immunosorbent assay (ELISA) and dot blot assay
Fresh-frozen mouse brain cortex was homogenized
in 4 volumes (wt:vol) of TBS extraction buffer (140
mM NaCl, 3 mM KCl, 25 mM Tris (pH 7.4), 5 mM
EDTA, and protease inhibitor cocktail (Roche Molecu-
lar Systems, Pleasanton, CA, USA)). Homogenate was
spun 100,000 g × 1 h, and the supernatant was saved
as the soluble fraction for A quantification. A40 and
A42 Human ELISA kits (InvitrogenTM Corporation,
Camarillo, CA, USA) were used to quantify the lev-
els of A40 and A42 peptides in the brain soluble
fractions. Quantitative determination was carried out
according to the manufacturer’s instructions, as pre-
viously described [13]. A40 and A42 levels were
normalized to the total amount of protein from each
individual sample (BCA method, Thermo Fisher Sci-
entific, Wilmington, DE, USA).
Ten micrograms of each soluble sample was applied
to nitrocellulose membranes using a 48-well Dot Blot
Manifold (Cleaver Scientific, Rugby, United King-
dom). The membranes were blocked with 10% nonfat
milk in TBS containing 0.01% Tween 20 at room tem-
perature for 1 h. The membranes were washed 3 times,
for 5 min each, with TBS containing 0.01% Tween 20
and incubated for 2 h at room temperature with rab-
bit polyclonal anti-prefibrillar oligomer antibody A11
(1:1000; Invitrogen Thermo-Fisher, Carlsbad, CA) or
with rabbit polyclonal anti-fibrillar oligomer antibody
OC (1:5000; Merck Millipore, Billerica, MA, USA).
After washing, the membranes were incubated for 1 h
with the appropriate horseradish peroxidase conju-
gated secondary antibody (1:2000; Dako), and immune
complexes were visualized with a chemiluminescence
reagent (electrochemiluminescence;Amersham).Den-
sitometric quantification was carried out with TotalLab




De-waxed sections were incubated with 98% formic
acid (3 min) for A immunofluorescence and then
treated with citrate buffer (20 min) to enhance anti-
genicity. Sections were stained with a saturated
solution of Sudan black B for 30 min (Merck Milli-
pore) to block lipofuscin autofluorescence, then rinsed
in 70% ethanol and washed in distilled water. After
a blockade with 10% fetal bovine serum (90 min),
the sections were incubated at 4◦C overnight with
combinations of primary antibodies against A (clone
6F/3D, mouse, 1:50, Dako), glial fibrillary acidic
protein (GFAP; rabbit, 1:250, Dako), IBA1 (rabbit,
1:250, Wako, Richmond, VA, USA) or fibrinogen (rab-
bit, 1:100, Abcam). After washing, the sections were
incubated with Alexa488 or Alexa546 fluorescence
secondary antibodies against the corresponding host
species (1:400, Molecular Probes, Eugene, OR, USA).
Then they were washed and mounted in Immuno-
Fluore Mounting medium (ICN Biomedicals, Solon,
OH, USA), sealed, dried overnight, and examined with
a Nikon Eclipse E800 microscope. The specific GFAP,
IBA1, and fibrinogen immunostaining density was cal-
culated in reference to the A plaque area in five
representative pictures taken of the cortex of each ani-
mal using the Adobe® Photoshop® CS4 software.
Quantitative PCR
1 g total RNA was reverse-transcribed with cDNA
synthesized with the High-Capacity cDNA Reverse
Transcription kit (Applied Biosystems). Quantifica-
tion of the mRNA levels was performed in duplicate
reactions with gene-specific TaqMan® probes and
the TaqMan® Universal PCR Master Mix (Applied
Biosystems). House-keeping genes used were Aars,
Hprt, and Xpnpep1 [14]. QPCR was performed using
the Applied Biosystems 7900HT Fast Real-Time PCR
System. Samples were analyzed with the double delta
CT (CT) method using vehicle-treated wild-type
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samples as control. Genes analyzed and probes are
shown in Supplementary Table 1.
Statistical analysis
Behavioral and gene expression data were analyzed
with two-way ANOVA with genotype and treatment
as between factors, followed by Bonferroni’s post hoc
test for multiple comparisons when required. Amyloid
and glial quantifications were analyzed with Student’s
t-test. In all the experiments, the significance level was
set at p < 0.05.
RESULTS
Fibγ377−395 peptide reduced cognitive deficits in
AβPP/PS1 mice
Intranasal administration of the Fib377−395 pep-
tide for 4 weeks at the early phase of the symp-
tomatic stage (6 months) reversed memory impairment
of APP/PS1 mice on the two-object recognition
test (Fig. 1). Two-way ANOVA revealed a signif-
icant treatment effect (F(1,19) = 8.493, p < 0.01) and
interaction between genotype and treatment factors
(F(1,19) = 8.784, p < 0.01). Subsequent post hoc com-
parisons revealed memory impairment in vehicle-
treated APP/PS1 mice with respect to wild-type litter-
mates(p < 0.01)andasignificantmemoryimprovement
in the Fib377−395 peptide-treated APP/PS1 when
compared to vehicle (p < 0.01). Total exploration time
onthe trainingandtestdays is includedinTable1, show-
ing no significant effect of genotype or treatment in the
exploratory behavior.
Aβ cortical was reduced in AβPP/PS1 mice
treated with Fib γ377−395 but no modification was
observed on Aβ vascular deposition and Aβ
soluble contents
The cortical A burden was significantly reduced
in Fib377−395 peptide-treated mice when compared
Fig. 1. Memory performance of animals treated during the early
symptomatic stage (6 months). APP/PS1 mice chronically treated
with vehicle exhibit a significant reduction in the recognition index
when compared to corresponding wild-type littermates. In con-
trast, chronic administration of Fib377−395 peptide induces memory
improvement in APP/PS1 compared to vehicle-treated mice. Data
are expressed as the mean values ± SEM. p < 0.01 genotype
effect; p < 0.01, compared to vehicle.
to vehicle-treated APP/PS1 mice (p < 0.05, Fig. 2A,
B). In contrast, the percentage of vessels showing
A deposition (Vehicle: 22.06 ± 3.74%; Fib377−395:
18.65 ± 3.41%; Fig. 2B) or A40 and A42 soluble
cortical contents were not significantly modified by
Fib377−395 peptide treatment (Fig. 2C). Similarly, no
difference was observed on the prefibrillar (A11 anti-
body) or fibrillar oligomer (OC antibody) contents in
soluble fractions of treated APP/PS1 mice evaluated
by dot blot (Fig. 2D).
Fib γ377−395 reversed the increase in fibrinogen
vascular deposition of AβPP/PS1 mice but did not
modify fibrinogen contents in Aβ plaques
The percentage of vessels showing fibrinogen depo-
sition was analyzed in treated mice. Two-way ANOVA
revealed a significant genotype effect (F(1,12) = 10.820,
p < 0.01) and interaction between genotype and treat-
ment factors (F(1,12) = 2.918, p < 0.01). Subsequent
Table 1
Total exploration time on the two-object recognition test
Exploration time Exploration time on training day (s)
on test day (s) Familiar object Novel Total
Treatment Genotype Mean SEM Mean SEM Mean SEM Mean SEM
Vehicle Wild-type 30.97 ± 6.97 6.49 ± 1.43 10.61 ± 1.96 17.10 ± 2.56
APP/PS1 21.48 ± 4.16 6.62 ± 1.54 5.60 ± 1.55 12.21 ± 3.06
Fibg355−377 Wild-type 23.81 ± 6.54 5.48 ± 1.94 12.80 ± 4.87 18.28 ± 6.73
APP/PS1 20.17 ± 5.12 4.52 ± 1.69 11.90 ± 3.58 16.42 ± 5.13
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Fig. 2. A) Total A burden in APP/PS1 mice is significantly reduced in cortex of Fib377−395 peptide-treated APP/PS1 mice. B) Representative
images of the A specific immunoreactivity in cortical sections of APP/PS1 mice treated with vehicle (left) or Fib377−395 (right). Asterisks:
A vascular deposition. Arrows: vessels without A deposits. Scale bars represent 200 m. C) Soluble A40 (left) and A42 (right) levels in
cortical homogenates from APP/PS1 mice are not significantly modified by the chronic treatment with Fib377−395. D) Fib377−395 peptide
does not modify the prefibrillar (A11 antibody) or fibrillar (OC antibody) oligomer contents in the soluble fraction of APP/PS1 mice cortical
homogenates, as revealed by dot blot. Counts are expressed as the mean values ± SEM. p < 0.05, treatment effect.
post hoc comparisons revealed a significant increase
in the vascular fibrinogen deposits in APP/PS1 mice
treated with vehicle respect to corresponding wild-
type controls (p < 0.01). Fib377−395 peptide treatment
reduced the percentage of vessels positive for fibrino-
gen immunostaining in APP/PS1 mice respect to
vehicle-treated animals (p < 0.001) (Fig. 3). In contrast,
no modification of fibrinogen staining in A plaques
was observed in treated APP/PS1 mice (Fig. 4). How-
ever, it is to note that fibrinogen staining in A plaques
was only revealed after formic acid pretreatment
of samples and when using an Alexa546 secondary
antibody against rabbit (fibrinogen) and Alexa488 sec-
ondary antibody against mouse (A), since the use of
the combination of an Alexa488 secondary antibody
against rabbit with an Alexa546 secondary antibody
against mouse resulted on no specific fibrinogen stain-
ing in A plaques.
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Fig. 3. Fib 377−395 peptide treatment reverses the increased percentage of vessels with fibrinogen deposition observed in APP/PS1 mice respect
to wild-type littermates. A) Representative images of the fibrinogen vascular deposition in vehicle (left) or Fib377−395-treated (right) mice.
Scale bar represents 200 m. Arrows: vessels without fibrinogen deposits. Asterisks: vessels with fibrinogen deposition. B) Quantification of the
percentage of vessels exhibiting fibrinogen deposits. Data are expressed as the mean values ± SEM. p < 0.01 genotype effect; p < 0.001,
compared to vehicle.
Table 2
mRNA expression levels of several cytokine-related genes involved in the inflammatory response in APP/PS1 mice
Cytokine-related genes Wild-type APP/PS1
Vehicle Fib377−395 Vehicle Fib377−395
Anti-inflammatory cytokines Il10ra 1.03 ± 0.11 1.00 ± 0.04 1.08 ± 0.11 1.08 ± 0.04
Il10rb 1.01 ± 0.06 1.00 ± 0.05 1.03 ± 0.08 1.07 ± 0.03
Tgfb1 1.02 ± 0.08 0.95 ± 0.08 1.22 ± 0.14 0.99 ± 0.08
Cell surface adhesion Itgb2 1.06 ± 0.16 1.22 ± 0.12 1.48 ± 0.19 1.51 ± 0.10
Chemokines Ccl3 1.03 ± 0.12 0.79 ± 0.09 5.25 ± 1.09∗∗ 3.32 ± 0.45∗∗∗
Ccl4 1.06 ± 0.17 0.96 ± 0.09 4.70 ± 1.01∗∗ 3.34 ± 0.42∗∗∗
Ccl6 1.03 ± 0.13 0.88 ± 0.10 3.04 ± 0.58∗∗ 1.99 ± 0.24∗∗
CxCl10 1.22 ± 0.40 1.91 ± 0.39 1.93 ± 0.34 2.73 ± 0.53
Complement system C1ql1 1.02 ± 0.08 0.86 ± 0.09 0.74 ± 0.06∗ 0.89 ± 0.10
C1qtnf7 1.04 ± 0.13 1.27 ± 0.15 1.06 ± 0.07 1.01 ± 0.10
C3ar1 1.03 ± 0.11 1.07 ± 0.06 1.45 ± 0.18 1.30 ± 0.06∗
C4b 1.07 ± 0.16 1.10 ± 0.12 1.66 ± 0.20∗ 1.40 ± 0.09
Colony stimulating factor receptors Csf1r 1.04 ± 0.13 0.94 ± 0.11 1.16 ± 0.16 1.02 ± 0.08
Csf3r 1.06 ± 0.16 0.84 ± 0.06 1.39 ± 0.25 1.23 ± 0.10∗∗
Fc receptors Fcgr1 1.02 ± 0.09 1.01 ± 0.09 1.27 ± 0.13 1.12 ± 0.07
Fcgr2b 1.03 ± 0.10 0.91 ± 0.05 1.10 ± 0.08 1.05 ± 0.04
Pro-inflammatory cytokines Il6st 1.02 ± 0.09 1.16 ± 0.14 1.07 ± 0.11 1.07 ± 0.06
Tnfrsf1a 1.04 ± 0.13 1.00 ± 0.18 1.18 ± 0.10 1.06 ± 0.09
Toll-like receptors Tlr4 1.02 ± 0.09 1.23 ± 0.14 1.05 ± 0.08 1.03 ± 0.05
Tlr7 1.03 ± 0.12 1.08 ± 0.21 1.36 ± 0.09∗ 1.14 ± 0.11
Others Arpc1b 1.01 ± 0.07 0.99 ± 0.05 1.22 ± 0.06∗ 1.05 ± 0.04§
Clec7a 1.08 ± 0.19 0.58 ± 0.06 6.53 ± 1.89∗ 4.10 ± 0.47∗∗∗
Cst7 1.06 ± 0.15 0.97 ± 0.20 33.71 ± 8.89∗∗ 20.14 ± 2.50∗∗∗
Cyba 1.03 ± 0.10 1.09 ± 0.06 1.36 ± 0.09∗ 1.32 ± 0.08∗
H2-Oa 1.03 ± 0.13 1.15 ± 0.06 1.60 ± 0.15∗ 1.57 ± 0.04∗∗∗
Values are calculated with the Ct method, using the mean of three housekeeping genes (Aars, Hprt, Xpnpep1) and vehicle-treated wild-types
as references. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 versus wild-type; §p < 0.05 versus Vehicle.
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Fig. 4. Fib 377−395 peptide does not modify the fibrinogen contents in A plaques of APP/PS1 mice. A) Representative images of the
fibrinogen staining in A plaques in vehicle (left) or Fib377−395-treated (right) mice. Scale bar represents 100 m. B) Quantification of the
fibrinogen staining in A plaques. Data are expressed as the mean values ± SEM.
Fibγ377−395 peptide did not modify the Aβ
deposition-related astroglia and microglia, or the
expression of a panel of genes involved in the
AβPP/PS1 inflammatory response
The number of astrocytes and microglia around
A plaques was not modified by Fib377−395 peptide
treatment in comparison to vehicle-treated APP/PS1
mice, as revealed by quantitative double-labeling
immunofluorescence (Fig. 5). To assess additional
molecular inflammatory changes associated with the
treatment, we evaluated the expression levels of a panel
of cytokine-related genes using quantitative PCR. As
shown in Table 2, vehicle-treated APP/PS1 mice
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Fig. 5. Fib377−395 peptide does not modulate glial response to A deposition. A) Representative images of double GFAP (red) and A (green)
immunoreactivity in cortical sections of APP/PS1 mice chronically treated with vehicle (left) or Fib377−395 (right). B) Quantification of the
GFAP staining around the A plaques reveals no significant treatment effect on the astroglial response in APP/PS1 mice. C) Representative
images of double IBA1 (red) and A (green) staining in APP/PS1 mice chronically treated with vehicle (left) or Fib377−395 peptide (right).
D) No significant effect on microglial response to A plaques is observed on Fib377−395 treated APP/PS1 mice. Scale bars represent 100 m.
Data are expressed as the mean values ± SEM.
exhibited marked modification of the expression of
several neuroinflammation-related genes when com-
pared to vehicle-treated WT animals. Treatment with
Fib377−395 did not produce significant modifications
in gene expression in WT and APP/PS1 animals.
DISCUSSION
Fibrinogen has emerged as a putative target against
vascular and A pathologies in AD since it has been
demonstrated that blocking its activity may reduce A
deposition in brain parenchyma and vessels, as well as
may decrease the inflammatory processes linked to AD
progression [1]. In line with these previous findings,
here we provide evidence of the therapeutic properties
at the cognitive level of the fibrinogen-derived peptide
Fib377−395 in an AD experimental model, the double
transgenic APP/PS1 mice.
This peptide was known to inhibit the interac-
tion between fibrinogen and the microglia integrin
receptor Mac-1 [15] and to reduce the exacerbated
inflammatory response in at least two models of
degenerative diseases [9–11]. For these reasons, an
anti-inflammatory effect was expected after a chronic
treatment with this compound in APP/PS1 mice,
in which an important inflammatory component is
present [16]. However, no modification in the num-
ber of astrocytes and microglia, and no regulation of
cytokine-related gene expression were observed in the
cortex of treated animals. These results suggest that
the interaction between fibrinogen and Mac-1 recep-
tor does not play a relevant role in the microglial
response in APP/PS1 mice and that further mecha-
nisms of action underlie the beneficial effects observed
in treated mice.
Fibrinogen is able to interact with A and enhance
A aggregation in the vascular vessel walls and in
brain parenchyma once leaked from damaged blood
vessels in AD [3, 4]. We observed reduced A depo-
sition in brain parenchyma but not in blood vessel
walls. However, decreased fibrinogen deposition was
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found in the cerebral blood vessels in APP/PS1 mice
treated with Fib377−395. Previous studies have shown
that this peptide is not able to efficiently inhibit the
capacity of fibrinogen to bind and to aggregate A pep-
tide [3], an observation supported in the present study
showing similar fibrinogen staining in A plaques in
treated mice. Therefore, we hypothesize that the reduc-
tion in cortical A plaque burden is related to the
reduction of fibrinogen leakage from damaged blood
vessels in Fib377−395-treated mice as suggested by
the reduction in the percentage of blood vessels with
fibrinogen deposits in Fib377−395-treated APP/PS1
mice. Moreover, a direct role of the Fib377−395 pep-
tide on A production can be probably ruled out since
no effect was observed either on total soluble A frac-
tion or in prefibrillar and fibrillar oligomer contents in
APP/PS1 mice. These observations give an advan-
tage to Fib377−395 over other specific A-fibrinogen
inhibitors recently reported to reduce vascular but not
parenchymal A deposition [17]. Together, the present
findings point to Fib377−395 as a potential therapeu-
tic compound in AD based on its beneficial effect
on cognition together with its capacity to retain full
coagulation function [9] thus proving low undesirable
side-effect profile.
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lioration of Duchenne muscular dystrophy in mdx mice by
elimination of matrix-associated fibrin-driven inflammation
coupled to the M2 leukocyte integrin receptor. Hum Mol
Genet 21, 1989-2004.
[12] Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales
V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997)
Accelerated amyloid deposition in the brains of transgenic
mice coexpressing mutant presenilin 1 and amyloid precursor
proteins. Neuron 19, 939-945.
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